INTERVENTION 1:	Intervention	0
Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel	Intervention	1
doxorubicin	CHEBI:28748,BAO:0000639	7-18
cyclophosphamide	CHEBI:4026	21-37
Doxorubicin + Cyclophosphamide, then Docetaxel	Intervention	2
doxorubicin	CHEBI:28748,BAO:0000639	0-11
cyclophosphamide	CHEBI:4026	14-30
INTERVENTION 2:	Intervention	3
Arm 2: Doxorubicin + Docetaxel	Intervention	4
doxorubicin	CHEBI:28748,BAO:0000639	7-18
Doxorubicin + Docetaxel	Intervention	5
doxorubicin	CHEBI:28748,BAO:0000639	0-11
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed invasive adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	34-48
breast	UBERON:0000310	56-62
Confined to the breast and ipsilateral axilla on clinical exam	Eligibility	2
breast	UBERON:0000310	16-22
Stage I, II, or IIIA (cT1-3, N0-1, M0)	Eligibility	3
At least one axillary lymph node with evidence of tumor on histologic exam	Eligibility	4
lymph	UBERON:0002391	22-27
Sentinel node biopsy allowed if followed by axillary dissection	Eligibility	5
No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven on biopsy to not be involved with tumor	Eligibility	6
No bilateral malignancy or mass in the opposite breast, unless mass is histologically proven to be benign	Eligibility	7
bilateral	HP:0012832	3-12
breast	UBERON:0000310	48-54
Must have undergone either a prior total mastectomy and axillary dissection (modified radical mastectomy) OR	Eligibility	8
radical	CHEBI:26519	86-93
Prior lumpectomy and axillary dissection	Eligibility	9
Patients must receive radiotherapy after randomization (not before) AND after chemotherapy	Eligibility	10
radiotherapy	OAE:0000235	22-34
Margins must be clear	Eligibility	11
No ipsilateral lymph nodes that are fixed to one another or to other structures (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are considered axillary nodes)	Eligibility	12
lymph	UBERON:0002391	15-20
lymph	UBERON:0002391	125-130
disease	DOID:4,OGMS:0000031	84-91
No histologically evident invasive tumor or ductal carcinoma in situ	Eligibility	13
ductal carcinoma in situ	HP:0030075,DOID:0060074	44-68
No diffuse tumors by mammography that would not be surgically amenable to lumpectomy	Eligibility	14
diffuse	HP:0020034	3-10
No other dominant mass in the ipsilateral breast remnant unless one of the following is true:	Eligibility	15
breast	UBERON:0000310	42-48
Histologically benign	Eligibility	16
Surgically removed with clear margins if malignant	Eligibility	17
No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude	Eligibility	18
erythema	HP:0010783	15-23
chest	UBERON:0001443	64-69
peau d'orange	HP:0025533	96-109
edema	HP:0000969	119-124
Tethering or dimpling of the skin or nipple inversion allowed	Eligibility	19
No metastatic disease	Eligibility	20
disease	DOID:4,OGMS:0000031	14-21
Skeletal pain allowed if bone scan negative for metastases	Eligibility	21
pain	HP:0012531	9-13
Hormone receptor status:	Eligibility	22
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Estrogen and progesterone status determined	Eligibility	23
estrogen	CHEBI:50114,BAO:0000760	0-8
progesterone	CHEBI:17026	13-25
PATIENT CHARACTERISTICS:	Eligibility	24
patient	HADO:0000008,OAE:0001817	0-7
Age:	Eligibility	25
age	PATO:0000011	0-3
greater than or equal to 18 years	Eligibility	26
Sex:	Eligibility	27
Female	Eligibility	28
female	PATO:0000383	0-6
Menopausal status:	Eligibility	29
Not specified	Eligibility	30
Performance status:	Eligibility	31
Not specified	Eligibility	32
Life expectancy:	Eligibility	33
At least 10 years, excluding diagnosis of cancer	Eligibility	34
cancer	DOID:162	42-48
Hematopoietic:	Eligibility	35
Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the investigator, this represents an ethnic or racial variation)	Eligibility	36
Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper limit of normal (ULN), significant underlying hematologic disorders must be excluded	Eligibility	37
platelet count	CMO:0000029	0-14
platelet count	CMO:0000029	48-62
excluded	HP:0040285	158-166
Hepatic:	Eligibility	38
Bilirubin no greater than ULN	Eligibility	39
Alkaline phosphatase less than 2.5 times ULN*	Eligibility	40
phosphatase	GO:0016791,BAO:0000295	9-20
SGOT less than 1.5 times ULN*	Eligibility	41
No nonmalignant systemic hepatic disease that would preclude study participation NOTE: *Alkaline phosphatase and SGOT cannot both be greater than ULN	Eligibility	42
disease	DOID:4,OGMS:0000031	33-40
phosphatase	GO:0016791,BAO:0000295	97-108
Renal:	Eligibility	43
Creatinine no greater than normal	Eligibility	44
creatinine	CHEBI:16737	0-10
No nonmalignant systemic renal disease that would preclude study participation	Eligibility	45
disease	DOID:4,OGMS:0000031	31-38
Cardiovascular:	Eligibility	46
No nonmalignant systemic cardiovascular disease that would preclude study participation	Eligibility	47
disease	DOID:4,OGMS:0000031	40-47
LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram	Eligibility	48
No active cardiac disease that would preclude use of doxorubicin or docetaxel, including the following:	Eligibility	49
active	PATO:0002354	3-9
disease	DOID:4,OGMS:0000031	18-25
doxorubicin	CHEBI:28748,BAO:0000639	53-64
Any prior myocardial infarction	Eligibility	50
myocardial infarction	HP:0001658,DOID:5844	10-31
Angina pectoris requiring anti-anginal medication	Eligibility	51
angina pectoris	HP:0001681	0-15
History of congestive heart failure	Eligibility	52
history	BFO:0000182	0-7
congestive heart failure	HP:0001635,DOID:6000	11-35
Cardiac arrhythmia requiring medication	Eligibility	53
arrhythmia	HP:0011675	8-18
Severe conduction abnormality	Eligibility	54
severe	HP:0012828	0-6
Valvular disease with documented cardiac function compromise	Eligibility	55
disease	DOID:4,OGMS:0000031	9-16
function	BAO:0003117,BFO:0000034	41-49
Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at least LLN	Eligibility	56
cardiomegaly	HP:0001640	0-12
chest	UBERON:0001443	16-21
ventricular hypertrophy	HP:0001714	31-54
Poorly controlled hypertension (diastolic greater than 100 mm/Hg)	Eligibility	57
hypertension	HP:0000822,DOID:10763	18-30
Hypertension well controlled by medication allowed	Eligibility	58
hypertension	HP:0000822,DOID:10763	0-12
Other:	Eligibility	59
No grade 2 or greater peripheral neuropathy	Eligibility	60
peripheral neuropathy	HP:0009830,DOID:870	22-43
No other prior malignancy within the past 5 years except:	Eligibility	61
Effectively treated squamous cell or basal cell skin cancer	Eligibility	62
skin cancer	DOID:4159	48-59
Surgically treated carcinoma in situ of the cervix	Eligibility	63
carcinoma	HP:0030731,DOID:305	19-28
Segmentally resected lobular carcinoma in situ of the ipsilateral or contralateral breast	Eligibility	64
lobular carcinoma in situ	HP:0030076,DOID:3010	21-46
breast	UBERON:0000310	83-89
Not pregnant or nursing	Eligibility	65
Negative pregnancy test	Eligibility	66
Fertile patients must use effective barrier contraception	Eligibility	67
No nonmalignant systemic disease that would preclude study participation	Eligibility	68
disease	DOID:4,OGMS:0000031	25-32
No diabetes with morning fasting blood glucose of 200 mg/dL or greater	Eligibility	69
blood	UBERON:0000178	33-38
glucose	CHEBI:4167,BAO:0000924	39-46
No psychiatric or addictive disorders that would preclude informed consent	Eligibility	70
No contraindication to corticosteroids that would preclude study participation	Eligibility	71
contraindication	OAE:0000055	3-19
PRIOR CONCURRENT THERAPY:	Eligibility	72
Biologic therapy:	Eligibility	73
No prior immunotherapy for breast cancer	Eligibility	74
breast cancer	DOID:1612	27-40
Chemotherapy:	Eligibility	75
No prior chemotherapy for breast cancer	Eligibility	76
breast cancer	DOID:1612	26-39
No prior anthracyclines or taxanes	Eligibility	77
No other concurrent investigational chemotherapy	Eligibility	78
Endocrine therapy:	Eligibility	79
No prior hormonal therapy for breast cancer	Eligibility	80
breast cancer	DOID:1612	30-43
No concurrent hormonal birth control methods or other hormonal therapy	Eligibility	81
No concurrent raloxifene, including for osteoporosis	Eligibility	82
raloxifene	CHEBI:8772	14-24
osteoporosis	HP:0000939,DOID:11476	40-52
Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator applied vaginally 3 times a week) allowed	Eligibility	83
estrogen	CHEBI:50114,BAO:0000760	28-36
estrogen	CHEBI:50114,BAO:0000760	63-71
estrogen	CHEBI:50114,BAO:0000760	91-99
week	UO:0000034	192-196
Radiotherapy:	Eligibility	84
radiotherapy	OAE:0000235	0-12
See Disease Characteristics	Eligibility	85
disease	DOID:4,OGMS:0000031	4-11
No prior radiotherapy for this malignancy	Eligibility	86
radiotherapy	OAE:0000235	9-21
Surgery:	Eligibility	87
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	88
disease	DOID:4,OGMS:0000031	4-11
No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy, mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy margins)	Eligibility	89
surgery	OAE:0000067	33-40
breast cancer	DOID:1612	45-58
Other:	Eligibility	90
No prior systemic therapy for this malignancy	Eligibility	91
No concurrent medications that alter cardiac conduction (e.g., digitalis, beta blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive heart failure (allowed if administered for other reasons [e.g., hypertension])	Eligibility	92
cardiac conduction	GO:0061337	37-55
arrhythmia	HP:0011675	130-140
congestive heart failure	HP:0001635,DOID:6000	153-177
hypertension	HP:0000822,DOID:10763	228-240
Concurrent bisphosphonates allowed	Eligibility	93
Outcome Measurement:	Results	0
Overall Survival	Results	1
[Not Specified]	Results	2
Time frame: 8 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel	Results	5
doxorubicin	CHEBI:28748,BAO:0000639	24-35
cyclophosphamide	CHEBI:4026	38-54
Arm/Group Description: Doxorubicin + Cyclophosphamide, then Docetaxel	Results	6
doxorubicin	CHEBI:28748,BAO:0000639	23-34
cyclophosphamide	CHEBI:4026	37-53
Overall Number of Participants Analyzed: 1753	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of patients alive  83	Results	9
Results 2:	Results	10
Arm/Group Title: Arm 2: Doxorubicin + Docetaxel	Results	11
doxorubicin	CHEBI:28748,BAO:0000639	24-35
Arm/Group Description: Doxorubicin + Docetaxel	Results	12
doxorubicin	CHEBI:28748,BAO:0000639	23-34
Overall Number of Participants Analyzed: 1753	Results	13
Measure Type: Number	Results	14
Unit of Measure: percentage of patients alive  79	Results	15
Adverse Events 1:	Adverse Events	0
Total: 66/1748 (3.78%)	Adverse Events	1
Febrile neutropenia 2/1748 (0.11%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Cardiac disorders - Other, specify 3/1748 (0.17%)	Adverse Events	3
Conduction disorder 0/1748 (0.00%)	Adverse Events	4
disorder	OGMS:0000045	11-19
Myocardial infarction 0/1748 (0.00%)	Adverse Events	5
myocardial infarction	HP:0001658,DOID:5844	0-21
Ventricular arrhythmia 1/1748 (0.06%)	Adverse Events	6
ventricular arrhythmia	HP:0004308	0-22
Left ventricular systolic dysfunction 0/1748 (0.00%)	Adverse Events	7
left ventricular systolic dysfunction	HP:0025169	0-37
Colitis 1/1748 (0.06%)	Adverse Events	8
colitis	HP:0002583,DOID:0060180	0-7
Diarrhea 0/1748 (0.00%)	Adverse Events	9
diarrhea	HP:0002014,DOID:13250	0-8
Duodenal ulcer 0/1748 (0.00%)	Adverse Events	10
duodenal ulcer	HP:0002588,DOID:1724	0-14
Adverse Events 2:	Adverse Events	11
Total: 43/1748 (2.46%)	Adverse Events	12
Febrile neutropenia 1/1748 (0.06%)	Adverse Events	13
neutropenia	HP:0001875,DOID:1227	8-19
Cardiac disorders - Other, specify 1/1748 (0.06%)	Adverse Events	14
Conduction disorder 0/1748 (0.00%)	Adverse Events	15
disorder	OGMS:0000045	11-19
Myocardial infarction 1/1748 (0.06%)	Adverse Events	16
myocardial infarction	HP:0001658,DOID:5844	0-21
Ventricular arrhythmia 0/1748 (0.00%)	Adverse Events	17
ventricular arrhythmia	HP:0004308	0-22
Left ventricular systolic dysfunction 1/1748 (0.06%)	Adverse Events	18
left ventricular systolic dysfunction	HP:0025169	0-37
Colitis 1/1748 (0.06%)	Adverse Events	19
colitis	HP:0002583,DOID:0060180	0-7
Diarrhea 1/1748 (0.06%)	Adverse Events	20
diarrhea	HP:0002014,DOID:13250	0-8
Duodenal ulcer 1/1748 (0.06%)	Adverse Events	21
duodenal ulcer	HP:0002588,DOID:1724	0-14
